Abstract 13545: MicroRNA-33b Knock-in Mice for an Intron of Sterol Regulatory Element-Binding Factor 1 (Srebf1) Exhibit Reduced HDL-C in vivo
Background: MicroRNAs (miRs) are small non-protein-coding RNAs that bind to specific mRNAs and inhibit translation or promote mRNA degradation. Recent reports, including ours, indicated that miR-33 (miR-33a) located within the intron of sterol regulatory element-binding protein (SREBP) 2 controls cholesterol homeostasis and can be a possible therapeutic target for treating atherosclerosis. Primates, but not rodents, express a second miR-33 gene (miR-33b) from an intron of SREBF1. To address miR-33b function in vivo, we developed humanized mice, in which a miR-33b transgene is inserted within a Srebf1 intron.
Methods and Results: The human miR-33b sequence was introduced into intron 16 of mouse Srebf1 by conventional gene targeting methods, because miR-33b is located in intron 16 of human SREBF1 and there are high homologies in exons 16 and 17 between human and mouse. We successfully established miR-33b knock-in (KI) mice with C57BL/6 background and this miR-33b KI strategy did not alter Srebf1 intron 16 splicing, which was confirmed by RT-PCR and sequencing. The expression of miR-33b in miR-33b KI hetero mice were almost half of those in miR-33b KI homo mice. An LXR agonist T0901317, which induces Srebf1 expression, enhanced miR-33b expression in primary hepatocytes and the liver of miR-33 KI homo mice. The protein levels of known miR-33a target genes, such as ABCA1, ABCG1, and SREBP-1, were reduced compared with those in wild-type mice. Peritoneal macrophages from the miR-33b KI mice had a reduced cholesterol efflux capacity via apoA-I and HDL-C. Serum HDL-C levels were reduced by almost 35% even in miR-33b KI hetero mice compared with wild-type mice. HPLC elution analysis showed that the decreased HDL levels were mainly composed of very large-, large-, medium sized HDL, which was compatible with the previous results of miR-33a deficient mice.
Conclusions: miR-33b KI mice for an intron of Srebf1 showed reduced HDL-C levels. These results indicate that miR-33b can be a potential target for raising HDL-C in humans and may account for lower HDL-C levels in humans than those in mice. These mice will aid in elucidating the roles of miR-33s in different disease models and in screening of the drugs that can alter miR-33a and miR-33b levels and activities.
Author Disclosures: T. Horie: None. T. Nishino: None. O. Baba: None. Y. Kuwabara: None. T. Nakao: None. M. Nishiga: None. S. Usami: None. M. Izuhara: None. F. Nakazeki: None. Y. Ide: None. S. Koyama: None. M. Yokode: None. T. Kita: None. T. Kimura: None. K. Ono: None.
- © 2014 by American Heart Association, Inc.